UCB's Cimzia touted as potential top-seller

Belgium's UCB is riding high today after it won the FDA nod for a new indication for Cimzia as a rheumatoid arthritis remedy. Company officials and some analysts said the drug could be an up-and-coming blockbuster. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.